Equities
Health CareHealth Care Equipment & Services
  • Price (EUR)19.09
  • Today's Change0.00 / 0.00%
  • Shares traded20.04k
  • 1 Year change19.31%
  • Beta--
Data delayed at least 15 minutes, as of Jul 09 2020 12:40 BST.
More ▼

Profile data is unavailable for this security.

About the company

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.

  • Revenue in EUR (TTM)534.70m
  • Net income in EUR55.20m
  • Incorporated2007
  • Employees2.73k
  • Location
    Fagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
  • Phone+32 80012880
  • Fax+32 92162491
  • Websitehttps://fagron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Puretech Health PLC8.66m371.76m910.22m300.002.431.542.77105.141.181.180.0271.860.0142--5.9325,925.7952.944.2166.316.05----3,732.69163.04----0.0570.00-52.7334.571,064.73--97.24--
Recipharm AB (publ)790.20m3.20m949.22m7.29k470.761.6611.121.200.26380.2638102.8474.810.4412.504.661,199,156.000.17931.520.20251.7547.0048.070.40662.771.502.220.708234.2317.0023.75115.1816.4511.35--
FAES Farma SA378.09m68.43m1.01bn1.44k14.46--12.282.680.24590.24591.35--------262,564.60--11.78--13.8363.0864.3818.1216.14--74.06----10.2013.2623.9820.3538.84--
Dottikon ES Holding AG164.40m31.19m1.02bn606.0032.102.6420.766.1926.4826.48139.56321.520.36680.47564.58288,399.306.965.497.876.1280.1782.6018.9714.811.58--0.000.0018.3212.61103.9790.2934.84--
Hansa Biopharma AB319.60k-36.54m1.05bn78.00--23.07--3,281.85-9.52-9.520.083311.840.0046--0.348445,027.03-52.99-38.19-57.02-41.5573.3585.18-11,431.57-4,954.36---164.280.0193--0.178715.76-45.18--23.28--
Clinigen Group PLC547.29m15.69m1.14bn130.0074.212.3215.722.080.10380.10383.683.320.51017.234.253,782,308.001.462.141.752.9642.7936.022.873.340.86476.890.45154.5319.8629.26-81.02-20.34-2.9016.67
AddLife AB353.69m15.31m1.18bn1.00k79.328.0532.543.341.411.4132.7013.941.145.235.753,956,438.004.98--8.51--34.69--4.37--0.493213.330.4178--40.21--8.74------
Zealand Pharma Aktieselskabet7.22m-83.71m1.29bn191.00--7.34--179.04-18.08-18.081.5733.010.0369--3,706.90300,279.30-42.82-12.24-50.73-13.75-----1,160.08-84.51----0.0769--8.84-23.11-198.32--39.22--
Karo Pharma AB218.12m5.30m1.30bn129.00249.052.3932.555.940.24090.240911.3725.120.2412----17,613,940.000.5883.690.7924.9351.7653.202.4415.21--1.630.28486.4617.71129.20-98.65--12.32--
Cosmo Pharmaceuticals NV62.48m-24.41m1.30bn245.00--3.18--20.78-1.77-1.774.5428.830.10324.973.93---4.057.99-4.168.4059.9166.30-39.1959.4918.86-1.380.2951---4.76-4.72-35.59--47.20--
Fagron NV534.70m55.20m1.38bn2.73k25.255.6816.212.580.7560.55597.323.360.72063.8712.90196,002.607.502.7710.164.9744.8944.2810.414.500.84335.820.613714.9413.363.6528.795.001.43-39.61
Laboratorios Farmaceuticos ROVI SA400.12m46.30m1.44bn1.31k30.494.2223.473.590.83960.83967.256.070.83861.185.45305,437.409.707.3412.249.5655.7458.3711.578.181.3233.810.185619.9925.769.88119.4610.2410.100.7117
Bavarian Nordic A/S120.97m35.90m1.53bn552.0030.072.2228.9612.656.486.4822.2387.710.15323.997.382,781,046.004.55-2.824.94-3.6142.2666.7929.68-9.593.447.840.4157--32.33-11.454.19--27.95--
Virbac SA938.34m51.55m1.67bn4.90k32.293.2115.781.786.116.11111.2961.410.72292.449.34191,615.704.181.895.952.7447.6545.145.782.890.65585.210.45420.007.993.95156.48-4.11-10.53--
BACHEM HOLDING AG295.10m50.95m1.74bn1.21k67.848.2823.465.913.913.9122.6732.010.49721.073.79259,697.808.588.1711.2510.4029.4831.1717.2716.551.0732.670.19381.8111.0511.2716.1213.2615.848.45
Siegfried Holding AG784.04m49.99m1.79bn2.41k34.972.6018.202.2912.5212.52196.45168.440.73382.733.50346,287.504.684.265.845.0320.7218.686.386.081.1010.130.163322.054.9421.46-5.626.63-5.47--
Data as of Jul 09 2020. Currency figures normalised to Fagron NV's reporting currency: Euro EUR

Institutional shareholders

32.57%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 05 Jun 20205.34m7.40%
NN Investment Partners BVas of 10 Apr 20204.80m6.64%
Capital International Ltd.as of 05 Jun 20202.20m3.05%
Evermore Global Advisors LLCas of 31 Mar 20202.16m2.99%
Norges Bank Investment Managementas of 29 May 20202.15m2.99%
Carmignac Gestion SAas of 07 Nov 20192.15m2.98%
The Vanguard Group, Inc.as of 31 May 20201.83m2.54%
KBC Asset Management NVas of 31 Dec 20191.07m1.48%
Amundi Asset Management SA (Investment Management)as of 30 Apr 2020903.63k1.25%
BNP Paribas Asset Management Belgium SAas of 30 Apr 2020890.69k1.23%
More ▼
Data from 31 Dec 2019 - 29 May 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.